openPR Logo
Press release

Lawsuit filed for Investors in shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP)

01-25-2022 11:00 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) shares.

A lawsuit was filed on behalf of investors in NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) shares.

An investor, who purchased shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), filed a lawsuit over alleged violations of Federal Securities Laws by NRx Pharmaceuticals, Inc.

Investors who purchased shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) have certain options and for certain investors are short and strict deadlines running. Deadline: March 21, 2022. NASDAQ: NRXP investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Wilmington, DE based NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The Company’s products include, among others, ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure.

In June 2021, NRx Pharmaceuticals, Inc. announced that it filed an application with U.S. Food and Drug Administration (“FDA”) requesting Emergency Use Authorization (“EUA”) for ZYESAMI (Aviptadil-acetate) to treat critically ill COVID-19 patients suffering with respiratory failure (the “ZYESAMI EUA Application”).

On November 4, 2021, NRx Pharmaceuticals, Inc. issued a press release “announc[ing] that the [FDA] has declined to issue an [EUA] for ZYESAMI® (aviptadil). The FDA stated that it was unable to issue the EUA at this time due to insufficient data regarding the known and potential benefits of the medicine and the known and potential risks of ZYESAMI in patients suffering from Critical COVID-19 with respiratory failure.”

Shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) declined from $13.49 per share on October 14, 2021, to as low as $5.60 per share on November 5, 2021.

According to the complaint the plaintiff alleges on behalf of purchasers of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) common shares between June 1, 2021 and November 4, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between June 1, 2021 and November 4, 2021, the Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the ZYESAMI EUA Application contained insufficient data regarding the potential benefits and risks of ZYESAMI; (ii) accordingly, the FDA was unlikely to approve the ZYESAMI EUA Application in its present form; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Those who purchased shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) here

News-ID: 2538320 • Views: 398

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Graphite Bio, Inc. (NASDAQ: G …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Graphite Bio, Inc. Investors who purchased shares of Graphite Bio, Inc. (NASDAQ: GRPH) and currently hold any of those NASDAQ: GRPH shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Graphite Bio, Inc. directors breached their fiduciary duties and caused
Romeo Power, Inc. (NYSE: RMO) Investor Notice: Update in Lawsuit against Romeo P …
The Shareholders Foundation announced an update in the lawsuit that is pending for certain investors in shares of Romeo Power, Inc. (NYSE: RMO). Investors who are current long term investors in Romeo Power, Inc. (NYSE: RMO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On April 16, 2021, a lawsuit was filed against Romeo Power, Inc. over alleged securities laws violations.
Investigation announced for Long-Term Investors in Standard Lithium Ltd. (NYSE: …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Standard Lithium Ltd. Investors who are current long-term investors in Standard Lithium Ltd. (NYSE: SLI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long-term investors in NYSE: SLI stocks follows a lawsuit filed against Standard Lithium Ltd. over
Match Group, Inc. (NASDAQ: MTCH) Shareholder Notice: Update in Lawsuit against M …
The Shareholders Foundation announced an update in the lawsuit that is pending for certain investors in Match Group, Inc. (NASDAQ: MTCH). Investors who purchased shares of Match Group, Inc. (NASDAQ: MTCH) and currently hold any of those NASDAQ: MTCH shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On October 3, 2019, a lawsuit was filed against Match Group Inc over alleged

All 5 Releases


More Releases for Pharmaceuticals

Cannabinoids Therapeutics-Pipeline Analysis 2018, Clinical Trials & Results | GW …
Cannabinoid is a type of alkaloid that is obtained from the cannabis sativaplants. Cannabis, also known as marijuana, produce resin containing compounds known as cannabinoids. Cannabinoids are being used for medical purposes from the ancient times. These are the active substance in Cannabis plants that produce pharmacological actions in the body that mostly involves central nervous system and immune system. Delta-9-THC (tetrahydrocannabinol) is the main active component of cannabinoids. Download the
Global Halal Pharmaceuticals Market 2019 - CCM Pharmaceuticals, Pharmaniaga, Ros …
This new report by Eon Market Research, titled “Global Halal Pharmaceuticals Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Halal Pharmaceuticals industry at a global as well as regional and country level. Key facts analyzed in this report include the Halal Pharmaceuticals market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study
Topical Antibiotic Pharmaceuticals Market 2016-2026 | Teva Pharmaceuticals, Perr …
Topical antibiotics are applied to a certain area of the skin to kill infections. Application of topical antibiotics has a number of advantages upon comparison of systemic delivery in the treatment of skin infections. Skin and soft tissue infections (SSTIs) involve microbial invasion of the skin and underlying soft tissues infections are one of the most commonly occurring conditions amongst people. Most of these infections are minor and chronic in
Halal Pharmaceuticals 2018 Global Market Key Players -CCM Pharmaceuticals, Pharm …
Halal Pharmaceuticals Market 2018 Wiseguyreports.Com Adds “Halal Pharmaceuticals – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2025” To Its Research Database. Description:  In this report, the global Halal Pharmaceuticals market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions,
Global RNAi for Therapeutic Market 2017 - Alnylam Pharmaceuticals, Arrowhead, Di …
Global RNAi for Therapeutic Market 2017 Analysis Report audits a Market Regions, Product Categories, with Sales, Business Revenue, Goods cost, RNAi for Therapeutic piece of the overall industry and Growth patterns, concentrating on driving RNAi for Therapeutic industry players, showcase size, request and supply examination, utilization volume, Forecast 2017 to 2022. Get Free Sample Copy of Report Here: https://goo.gl/1sB8Bi Top Manufacturers Analysis of This Report Alnylam Pharmaceuticals Arrowhead Dicerna Pharmaceuticals Mirna Therapeutics Quark Pharmaceuticals RXi Pharmaceuticals miRagen Therapeutics Gradalis Sirnaomics The Global
Opioids Drugs Market 2016 - Johnson & Johnson, Teva pharmaceuticals, Purdue Phar …
Market Research Report on Opioids Drugs Market 2016 is a professional and in-depth study on the current state of the Opioids Drugs worldwide. First of all, " Global Opioids Drugs Market 2016 " report provides a basic overview of the Opioids Drugs industry including definitions, classifications, applications and Opioids Drugs industry chain structure. Major Companies Covered in this report:- Johnson & Johnson Teva pharmaceuticals Purdue Pharma King Pharmaceuticals Orexo Pharmaceuticals Endo Pharmaceuticals Get Sample Copy Of Report @